The future of payer engagement in pharma: rethinking how value is communicated

Three forces are reshaping what effective payer engagement looks like, and why the traditional model, while still valuable, increasingly needs to be complemented with digital approaches.

These trends create both a challenge and an opportunity for market access teams to communicate value. Reaching stakeholders effectively requires a more segmented approach than most teams have historically had the tools to deliver.

A broader shift is emerging as value communication evolves into a strategic discipline in its own right – closely linked but distinct to health economics, commercial strategy and medical affairs. For decades, “communicating value” was something that happened at the end of the development pipeline: the evidence was generated, the dossier was written, the account manager and field team members delivered the message.

Today, the ability to articulate and demonstrate product value across stakeholders has moved to the center of competitive strategy, for several converging reasons:

Regulatory and reimbursement pressure is intensifying on all fronts. In the U.S., the Inflation Reduction Act’s Medicare price negotiations are projected to reduce pharmaceutical company revenues by 31% through 2039, making the value argument for every dollar of pricing more consequential [6]. In Europe, the EU Joint Clinical Assessment regulation signifies a new pan-European requirement that organizations must engage with structured, evidence-rich value narratives [7][8]. Across markets, local payers continue to tighten cost-effectiveness thresholds and demand more granular evidence of real-world benefit.

At the same time, the therapies themselves demand more sophisticated value stories. When 72% of new drug approvals carry orphan designations and specialty medicines account for 93% of U.S. launches, the value conversation can’t rely on broad population-level arguments.[1] It needs to address specific patient subgroups, novel endpoints, immature survival data, and outcomes that may take years to materialize – all while justifying pricing.

As a result, value communication now spans the entire product lifecycle and touches multiple audiences, each with different evidence needs. Organizations that invest in dedicated tools and platforms to deliver this are better positioned than those that treat it as a byproduct of other activities.

Healthcare decision-makers have already made the shift: the vast majority consider digital payer engagement in pharma essential to their formulary work. Stakeholders engage with digital resources more than twice as long as offline materials, and consistently favor them for placement decisions [9][10][11]. Despite this demand, pharma-backed digital resources specifically designed for formulary decision-makers remain relatively rare.

To close the gap, it is critical to understand what the evidence is telling us about payer preferences:

Payers want to explore data, not just receive it. Over half of formulary committee members say that interactive content makes meetings with account managers more valuable. The deeper insight is why. Payers don’t just want to see results; they want to test them against their own reality.

When an economic model recalculates in real-time as they input their own numbers (their patient population, their current spending, their coverage mix), the conversation shifts from “here’s what our product is worth” to “let’s figure out together what this means for your organization.” That requires real analytical depth below the surface, not just well-designed static outputs [11].

Payers want to engage earlier, not just at launch. Payers increasingly want to understand product value a year or more before expected approval, so they can plan budgets and coverage decisions in advance. Organizations that wait until launch to start the conversation are already behind, but regulatory constraints demand a strategic approach to remain compliant [12].

Payers want content shaped to their specific situation. A hospital formulary committee has different needs compared to an insurer or a pharmacy benefit manager. Some prioritize disease-area trend reports; others want to interact directly with budget models. It’s not enough to segment messages by audience. Each decision-maker needs to see the evidence through the lens of their own priorities, constraints, and patient mix [11].

Field-based account managers remain the backbone of payer engagement in pharma. And those relationships are irreplaceable. But two structural realities limit what even the best field teams can do independently.

Account managers are typically assigned by account, not by product. A single manager may be responsible for communicating the value of dozens of products across multiple disease areas. When the clinical evidence, economic models, and scenarios for each product live within a single platform, the manager can navigate to the depth the conversation demands on any product – without needing to process all that complexity themselves.

Payer conversations increasingly center on budget impact, cost-effectiveness, and incremental value. The issue is, payers typically have deeper technical expertise in these areas than the account managers in front of them. But when a manager can walk a payer through a live economic model, adjust inputs together, and explore scenarios in real-time, the conversation shifts from a presentation to a collaboration. A digital payer engagement tool embeds that expertise in validated models running in the background; the manager doesn’t need to be a health economist.

These challenges are especially acute outside the largest U.S. accounts. In markets where teams are small or payer access is limited (which accounts for most of the world), having digital payer engagement tools becomes the primary way to demonstrate value. And case studies show that smaller companies with such platforms can generate deeper engagement compared with larger competitors relying on traditional channels [9].

The solution to both challenges is the same: a single platform that brings together clinical evidence, economic models, and payer-specific context. And crucially, a tool that evolves as the product moves through its lifecycle.

What makes this approach different from simply digitizing a slide deck? Platforms that drive meaningful payer engagement are built around the decision, rather than around the content:

They embed actual economic models in the backend (budget impact, cost-effectiveness, treatment pathway simulations) that automatically recalculate LIVE when a payer adjusts inputs. This is what separates them from digital collateral tools – which deliver content but don’t compute anything – and from dashboards – which visualize historical data but don’t run economic models.

Clinical data, economic models, and payer-specific inputs co-exist in a single environment. A payer can move from reviewing trial results, to exploring budget impact, to modeling a coverage scenario. And it’s all powered by the same analytical engine.

When decision-makers bring their own assumptions and scenarios into the engagement, they’re not receiving a pitch. They’re reaching conclusions through their own analysis, which is where confidence is built.

Knowing which evidence a payer engaged with most, which inputs they adjusted, and which scenarios they explored gives a much clearer picture of what’s driving their thinking. Simply knowing that the payer downloaded a document provides no such insight.

Payer communications are regulated. Best-in-class payer engagement tools have built-in guardrails for medical, legal, and regulatory review, with clear audit trails and version control.

To date, the pharmaceutical industry has heavily invested in digital transformation across R&D, commercial, and medical affairs. Payer engagement in pharma is the next frontier. And this is arguably the area where digital payer engagement tools can have the most direct impact on commercial outcomes. Teams that get payer engagement strategies right won’t just reach more payers. They’ll be directly part of how those payers think through their decisions.

Best practice digital payer engagement tools like BaseCase are helping field teams and account managers revolutionize how they communicate value. The BaseCase platform converts static health economic models into interactive experiences that combine value frameworks, economic modeling, and real-world evidence. The result: teams are armed with the tools to present stronger, more compelling cases for coverage and reimbursement.